The Evidence Trail

Open the black box

Walk through how the platform reasons through a real clinical question — from an uploaded history to ranked, ICD-coded diagnoses and a safety-validated recommendation. Every line traceable to cited evidence.

Cited claims retrieved
15
Quality-scored CKOs across evidence tiers
Ranked hypotheses
5
Each with an ICD-10 code and rationale
Safety flag surfaced
1
G6PD medication/exposure risk
Unsupported claims
0
Every statement traceable to source

An anonymized case, step by step

A real patient case, de-identified — the physician asked whether a 47-year-old longevity patient should start tesamorelin. Every stage of the platform's reasoning is shown exactly as it ran.

Clinical question

Can this patient take tesamorelin? Will he benefit?

Confidence 78%Human review required
Age
47
Sex
Male
Focus
Longevity / prevention
Chart flag
G6PD deficiency

A 47-year-old male is loaded from three uploaded documents. There is no active complaint — the goal is to optimize healthspan, function, and prevention rather than treat an illness. One chart flag carries forward: a known G6PD deficiency, surfaced as a medication/exposure risk rather than an allergy. Asymptomatic by report; history is patient-reported and not yet clinician-verified.

Before reasoning, the engine commits to an explicit plan. Every later step is traceable back to it.

  1. 1process_patient_data·Analyze demographics, symptoms, and medical history
  2. 2query_knowledge_base·Search clinical protocols and research for relevant evidence
  3. 3search_web·Search external medical literature for supplemental evidence
  4. 4diagnostic_reasoning·Generate diagnostic hypotheses and treatment recommendations
  5. 5clinical_validation·Validate safety, check contraindications, and assess confidence
Key findings
  • Known G6PD deficiency — oxidative-stress vulnerability requiring medication/food/chemical precautions and hemolysis monitoring.
  • Lab pattern reported: low RBC/HGB/HCT with elevated MCV, consistent with macrocytic anemia (etiology not provided).
  • Iron studies abnormality: elevated serum iron and ferritin — suggests iron loading / inflammation / hemolysis rather than simple iron deficiency.
  • Asymptomatic, prevention-focused; no chronic-disease history reported, but history is patient-reported and not clinician-verified.
  • No medication or supplement list available — clinically relevant given G6PD exposure risks and possible macrocytosis contributors.
Abnormalities
  • Macrocytic anemia: decreased RBC/HGB/HCT with increased MCV.
  • Elevated iron and ferritin (iron-overload signal vs. acute-phase response / hemolysis recycling).
Risk factors
G6PD oxidative triggersB12 / folate deficiencyLiver / alcohol effectIron-loading tendency
AI clinical insight

G6PD deficiency plus macrocytic anemia with elevated iron/ferritin raises a flag for red-cell stress or impaired erythropoiesis rather than simple iron deficiency. Macrocytosis also points to B12/folate deficiency, alcohol/liver effects, thyroid dysfunction, or marrow stress — clarifying the driver matters before any longevity intervention that could increase metabolic demand.

Can this patient take tesamorelin? Will he benefit?

15 retrieved
EndoManualTier 1relevance 0.90

The first approach to differential diagnosis of thyroid disorders is the measurement of free T4 and TSH.

Hypothyroid_symptoms_and_the_likelihood_of_HTTier 1relevance 0.80

Diagnosis was verified if patients had sustained hypothyroidism three weeks or later and/or T4 substitution therapy was initiated.

GHRH_and_cognition (Arch Neurol, RCT)Tier 1relevance 0.72

Participants were randomized 1:1 to 1.0 mg/d of tesamorelin (GHRH) or placebo subcutaneously 30 minutes before bedtime for 20 weeks.

Literature summary

Peptide therapy shows clinical evidence for supporting healthspan, cognition, immune function, and tissue repair — with the consistent caveat that protocols belong under monitored clinical supervision with baseline labs.

1

Climbing the longevity pyramid: overview of evidence-driven approaches

PubMedpmc.ncbi.nlm.nih.gov

Longevity medicine is an emerging, iterative discipline focusing on early detection, preventive measures, and personalized approaches.

2

Potential role of bioactive peptides in prevention and treatment

PubMedpmc.ncbi.nlm.nih.gov

Bioactive peptides have demonstrated significant antihypertensive and lipid-lowering activity in clinical trials.

3

Peptides for Longevity: What the Evidence Actually Shows

Webgethealthspan.com

Clinical supervision is what separates a protocol from a gamble — labs first, then a monitored, individualized protocol.

Ranked diagnostic hypotheses
Macrocytic anemia, unspecified, with iron-overload patternD53.9
50%

Low RBC/HGB/HCT with increased MCV plus elevated iron and ferritin is not typical of iron deficiency. Raises concern for B12/folate deficiency, alcohol-related marrow toxicity, hypothyroidism, liver disease, medication effect, myelodysplasia, or hemolysis. Despite “no symptoms,” this is a clinically significant incidental finding requiring workup before any GH-axis optimization.

  • Patient labs (observational): macrocytosis with anemia and high iron/ferritin
  • Mechanistic: ineffective erythropoiesis (e.g. B12/folate) can raise iron indices
Other acquired hemolytic anemias (possible episodic hemolysis in G6PD deficiency)D59.8
18%

Known G6PD deficiency raises risk of oxidative-triggered hemolysis; anemia is present though hemolysis markers were not provided. Reticulocytosis can artifactually raise MCV; high ferritin can reflect iron recycling post-hemolysis. Needs a hemolysis panel and reticulocyte count.

  • Patient history: confirmed G6PD deficiency
  • Mechanistic: oxidative stress → RBC membrane damage → hemolysis
Hypothyroidism, unspecified (incl. consideration of central hypothyroidism)E03.9
12%

Knowledge base emphasizes thyroid assessment as first-line (TSH + free T4) and notes risk of missed central hypothyroidism. Hypothyroidism can cause macrocytosis and the dyslipidemia/weight changes that often motivate “optimization” therapies.

  • KB (evidence 86/100): first approach is TSH + free T4
  • KB (evidence 82/100): bioactive-TSH concept for primary/central hypothyroidism
Alcoholic / other chronic liver disease causing macrocytosis and hyperferritinemiaK70.9
10%

Macrocytosis and elevated ferritin can occur with alcohol use and liver disease. Lifestyle (alcohol) and LFTs were not provided — a common, high-yield cause to rule in or out.

  • Mechanistic: alcohol/liver injury → macrocytosis + elevated ferritin
Myelodysplastic syndrome, unspecifiedD46.9
6%

Less common at 47, but must be considered with unexplained macrocytic anemia, especially if persistent or with other cytopenias. If anemia persists after nutritional/endocrine/liver/hemolysis causes are excluded, hematology evaluation is indicated.

  • Observational: persistent unexplained macrocytosis warrants MDS evaluation
Treatment recommendations
Defer tesamorelin (GHRH analog) until anemia/macrocytosis and thyroid status are clarified
Evidence: Mechanistic rationale — KB has no tesamorelin-specific evidence for this case

Tesamorelin raises endogenous pulsatile GH → IGF-1, but GH/IGF-1 activation can mask underlying drivers of fatigue/body composition and may be inappropriate with unrecognized disease. The biology to address first is the unexplained macrocytic anemia.

Levothyroxine (T4) only if hypothyroidism confirmed — standard of care, not a peptide
Evidence: Human RCT / observational (standard endocrine therapy)

If hypothyroidism is present, replacing T4 normalizes thyroid signaling, improving erythropoiesis (may help macrocytosis), lipid metabolism, and energy — addressing a root driver that can mimic “low vitality.”

Validation checks
Defer tesamorelin (GHRH analog)
Allergy: PASSContraindication: PASS
Levothyroxine (T4) if hypothyroidism confirmed
Allergy: PASSContraindication: PASS
Warnings
  • This is an AI-generated analysis. Always consult a qualified healthcare professional.
  • The primary issue is not “optimization” — an abnormal lab signal (macrocytic anemia with elevated iron/ferritin) requires evaluation before elective peptide protocols.
  • Tesamorelin: the knowledge base contains no tesamorelin-specific safety/efficacy evidence for this case; any use would be off-label and should not proceed without full screening.
  • G6PD deficiency: maintain strict avoidance of oxidative triggers and educate the patient on hemolysis warning signs; verify all supplements/OTCs.
AI safety assessment

Deferring tesamorelin is prudent: it is FDA-approved only for HIV-associated lipodystrophy and is otherwise off-label/investigational, can worsen glucose tolerance, and may unmask endocrine pathology — so anemia/macrocytosis and thyroid status should be clarified first. Levothyroxine is standard of care only with confirmed hypothyroidism. Monitor CBC with indices, B12/folate ± MMA/homocysteine, reticulocytes, and TSH/free T4.

Anonymized from a real patient case, shown exactly as the platform produced it. AI-generated analysis — not a substitute for clinical judgment.

The report it generates

Beyond answering a single question, the platform compiles a clinician-ready, medical-grade report for the same patient — not a chat transcript. Here is the full profile a physician can download and act on.

Everything below is reproduced in the downloadable report — the same medical-grade PDF export a clinician receives, fully de-identified.

Download sample report (PDF)

Integrative Medicine AI

Clinical Decision Support Report

Sample · De-identified

Clinical question

Can this patient take tesamorelin? Will he benefit?

Confidence 78%Human review required
Patient
Sample Patient
Age
47 years
Sex
Male
Focus
Longevity & healthspan optimization

1 · Key findings

  • Known G6PD deficiency — oxidative-stress vulnerability requiring medication/food/chemical precautions and hemolysis monitoring.
  • Lab pattern reported: low RBC/HGB/HCT with elevated MCV, consistent with macrocytic anemia (etiology not provided).
  • Iron studies abnormality: elevated serum iron and ferritin — suggests iron loading / inflammation / hemolysis rather than simple iron deficiency.
  • Asymptomatic, prevention-focused; no chronic-disease history reported, but history is patient-reported and not clinician-verified.
  • No medication or supplement list available — clinically relevant given G6PD exposure risks and possible macrocytosis contributors.
  • Macrocytic anemia: decreased RBC/HGB/HCT with increased MCV.
  • Elevated iron and ferritin (iron-overload signal vs. acute-phase response / hemolysis recycling).

G6PD deficiency plus macrocytic anemia with elevated iron/ferritin raises a flag for red-cell stress or impaired erythropoiesis rather than simple iron deficiency. Macrocytosis also points to B12/folate deficiency, alcohol/liver effects, thyroid dysfunction, or marrow stress — clarifying the driver matters before any longevity intervention that could increase metabolic demand.

2 · Ranked differential diagnosis

Macrocytic anemia, unspecified, with iron-overload patternD53.9
50%

Low RBC/HGB/HCT with increased MCV plus elevated iron and ferritin is not typical of iron deficiency. Raises concern for B12/folate deficiency, alcohol-related marrow toxicity, hypothyroidism, liver disease, medication effect, myelodysplasia, or hemolysis. Despite “no symptoms,” this is a clinically significant incidental finding requiring workup before any GH-axis optimization.

Other acquired hemolytic anemias (possible episodic hemolysis in G6PD deficiency)D59.8
18%

Known G6PD deficiency raises risk of oxidative-triggered hemolysis; anemia is present though hemolysis markers were not provided. Reticulocytosis can artifactually raise MCV; high ferritin can reflect iron recycling post-hemolysis. Needs a hemolysis panel and reticulocyte count.

Hypothyroidism, unspecified (incl. consideration of central hypothyroidism)E03.9
12%

Knowledge base emphasizes thyroid assessment as first-line (TSH + free T4) and notes risk of missed central hypothyroidism. Hypothyroidism can cause macrocytosis and the dyslipidemia/weight changes that often motivate “optimization” therapies.

Alcoholic / other chronic liver disease causing macrocytosis and hyperferritinemiaK70.9
10%

Macrocytosis and elevated ferritin can occur with alcohol use and liver disease. Lifestyle (alcohol) and LFTs were not provided — a common, high-yield cause to rule in or out.

Myelodysplastic syndrome, unspecifiedD46.9
6%

Less common at 47, but must be considered with unexplained macrocytic anemia, especially if persistent or with other cytopenias. If anemia persists after nutritional/endocrine/liver/hemolysis causes are excluded, hematology evaluation is indicated.

3 · Recommendations

Defer tesamorelin (GHRH analog) until anemia/macrocytosis and thyroid status are clarified

Evidence: Mechanistic rationale — KB has no tesamorelin-specific evidence for this case

Tesamorelin raises endogenous pulsatile GH → IGF-1, but GH/IGF-1 activation can mask underlying drivers of fatigue/body composition and may be inappropriate with unrecognized disease. The biology to address first is the unexplained macrocytic anemia.

Levothyroxine (T4) only if hypothyroidism confirmed — standard of care, not a peptide

Evidence: Human RCT / observational (standard endocrine therapy)

If hypothyroidism is present, replacing T4 normalizes thyroid signaling, improving erythropoiesis (may help macrocytosis), lipid metabolism, and energy — addressing a root driver that can mimic “low vitality.”

4 · Recommended work-up

1Repeat CBC with differential and RBC indices — confirm macrocytosis and degree of anemia.
2Peripheral blood smear — macro-ovalocytes, hypersegmented neutrophils, schistocytes; platelet/WBC review.
3Reticulocyte count and index — distinguish hypoproliferation from hemolysis.
4Hemolysis panel — LDH, haptoglobin, total and indirect bilirubin.
5Vitamin B12, folate (RBC folate), methylmalonic acid, homocysteine.
6Iron studies with transferrin saturation (TSAT); repeat ferritin.
7Liver panel — AST/ALT, GGT, ALP, bilirubin.
8Thyroid — TSH + free T4 as first-line (knowledge-base supported); free T3 if indicated.
9Metabolic risk — hs-CRP, fasting glucose/insulin, HbA1c, lipids with ApoB and Lp(a).
10G6PD enzyme activity confirmation — avoid testing during acute hemolysis (false-normal risk).
11If ferritin/TSAT persistently elevated — HFE testing for hereditary hemochromatosis.

5 · Safety flag

G6PD deficiency

Medication / exposure flag — not an allergy

G6PD deficiency is not an allergy, but it matters when selecting medications or interpreting symptoms such as sudden fatigue, jaundice, dark urine, pallor, shortness of breath, or unexplained anemia. The patient should disclose it to clinicians, dentists, urgent-care clinicians, and pharmacists before starting new medications, and avoid known oxidative triggers. Medication-avoidance lists and severity interpretation must be confirmed by a licensed clinician.

6 · Clinical validation

Defer tesamorelin (GHRH analog)
Allergy: PASSContraindication: PASS
Levothyroxine (T4) if hypothyroidism confirmed
Allergy: PASSContraindication: PASS
  • This is an AI-generated analysis. Always consult a qualified healthcare professional.
  • The primary issue is not “optimization” — an abnormal lab signal (macrocytic anemia with elevated iron/ferritin) requires evaluation before elective peptide protocols.
  • Tesamorelin: the knowledge base contains no tesamorelin-specific safety/efficacy evidence for this case; any use would be off-label and should not proceed without full screening.
  • G6PD deficiency: maintain strict avoidance of oxidative triggers and educate the patient on hemolysis warning signs; verify all supplements/OTCs.

Deferring tesamorelin is prudent: it is FDA-approved only for HIV-associated lipodystrophy and is otherwise off-label/investigational, can worsen glucose tolerance, and may unmask endocrine pathology — so anemia/macrocytosis and thyroid status should be clarified first. Levothyroxine is standard of care only with confirmed hypothyroidism. Monitor CBC with indices, B12/folate ± MMA/homocysteine, reticulocytes, and TSH/free T4.

7 · Evidence sources

EndoManualTier 1relevance 0.90

The first approach to differential diagnosis of thyroid disorders is the measurement of free T4 and TSH.

Hypothyroid_symptoms_and_the_likelihood_of_HTTier 1relevance 0.80

Diagnosis was verified if patients had sustained hypothyroidism three weeks or later and/or T4 substitution therapy was initiated.

GHRH_and_cognition (Arch Neurol, RCT)Tier 1relevance 0.72

Participants were randomized 1:1 to 1.0 mg/d of tesamorelin (GHRH) or placebo subcutaneously 30 minutes before bedtime for 20 weeks.

Summary

A 47-year-old male presents for longevity optimization and asks whether to start tesamorelin. The dominant clinical signal is not “optimization” but an unexplained macrocytic anemia with elevated iron and ferritin, compounded by known G6PD deficiency. The recommendation is to defer tesamorelin — off-label here and not anchored to knowledge-base evidence — and first clarify the anemia and thyroid status through the targeted work-up below. Levothyroxine is reserved for confirmed hypothyroidism. Confidence is moderate (78%); the analysis is flagged for clinician review.
Sample, de-identified. A real analysis generated by the platform with the patient name and all direct identifiers removed. Patient history is patient-reported and not a substitute for a clinician-verified medical record.

Sample, de-identified. A real analysis generated by the platform with the patient name and all direct identifiers removed.

How evidence scoring works

Every claim carries an evidence tier and a quality score from 0 to 1. Higher-tier evidence is weighted more heavily during retrieval and reasoning; claims below threshold are suppressed before they ever reach the clinician.

Meta-analysis / Systematic Review0.90 – 1.00
Randomized Controlled Trial0.75 – 0.95
Cohort / Observational0.55 – 0.80
Case Study / Series0.35 – 0.60
Expert Opinion0.20 – 0.45

Want to see this with your own cases?

Schedule a 30-minute demo and walk through a real clinical case with our team.

Request a Demo